Abstract
Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.
Author supplied keywords
Cite
CITATION STYLE
APA
Lyles, A. (2015). Biosimilars: patient and physician acceptability is the fifth hurdle to market competition. GaBI Journal. Pro Pharma Communications International. https://doi.org/10.5639/gabij.2015.0401.002
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free